Agios Pharmaceuticals Files 8-K
Ticker: AGIO · Form: 8-K · Filed: Aug 4, 2025 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | 8-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
TL;DR
Agios filed an 8-K for a Reg FD disclosure on Aug 4, 2025. No major news yet.
AI Summary
On August 4, 2025, Agios Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, with no specific financial transactions or material events detailed in the provided excerpt. The report was filed as of August 4, 2025.
Why It Matters
This filing serves as a notification to the SEC and the public about a Regulation FD Disclosure, ensuring transparency in company communications.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate financial or operational impact.
Key Players & Entities
- AGIOS PHARMACEUTICALS, INC. (company) — Filer
- August 4, 2025 (date) — Date of Report
- 001-36014 (company) — SEC File Number
- 88 Sidney Street, Cambridge, MA 02139 (company) — Business Address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure.
What is the exact date of the earliest event reported?
The date of the earliest event reported is August 4, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 88 Sidney Street, Cambridge, MA 02139.
What is the SEC file number for Agios Pharmaceuticals, Inc.?
The SEC file number for Agios Pharmaceuticals, Inc. is 001-36014.
What is the Standard Industrial Classification code for Agios Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Agios Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding AGIOS PHARMACEUTICALS, INC. (AGIO).